



For Further Information Contact:  
Bioject Medical Technologies Inc.  
Ralph Makar  
President and CEO  
503-692-8001 ext. 4137

Chris Farrell  
Vice President of Finance  
503-692-8001 ext. 4132

## **BIOJECT TO REPORT SECOND QUARTER 2008 FINANCIAL RESULTS**

**PORTLAND, OR** July 30, 2008 – Bioject Medical Technologies Inc., (OTCBB: BJCT), a leading developer of needle-free injection therapy systems, announced today that the Company will report its financial results for the second quarter ended June 30, 2008 on Wednesday, August 6, 2008, after the close of the financial markets. Management will conduct a conference call on Thursday, August 7, 2008 at 10:00 a.m. Eastern Time to review the results for the quarter. Ralph Makar, President and CEO, Dr. Rick Stout, Executive Vice President and Chief Medical Officer and Chris Farrell, Vice President of Finance, will be hosting the call.

Live audio of the conference call will be available to investors, members of the news media and the general public. To participate in the call via telephone, please dial 1-877-407-8037. A conference call replay will also be available until August 14, 2008. To listen to the replay, please dial 1-877-660-6853, replay account number 7303, identification number 292351.

Bioject Medical Technologies Inc., based in Portland, Oregon, is an innovative developer and manufacturer of needle-free injection therapy systems (NFITS). NFITS provide an empowering technology and works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The Company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.

For more information about Bioject, visit: [www.bioject.com](http://www.bioject.com).